Company Short-Term Debts: Inventiva Pharma (IVA)

The business viability of Inventiva S.A. (IVA) relies on the success of the final testing stages for new drugs and the support of venture capital funds. The current development vector is focused on finalizing large-scale Phase 3 trials to facilitate subsequent partnerships with global players. This price chart, which stands at 0.02, highlights the long-term potential of liver metabolic disorder therapies amid stable demand.

Short-term debt measures the total liabilities maturing within one year, determining the risk of liquidity loss. The trend of total short-term obligations on the GURU.Markets platform reflects the company's ability to manage cash flows. The current value of 0.02 captures the volume of short-term financing. For Inventiva S.A. (IVA), this metric is critical, as costly developments in hepatology require stable capital. Debt control prevents cash flow gaps during the creation of fibrosis therapy.